Bortezomib treatment for refractory nontuberculous mycobacterial infection in the setting of interferon gamma autoantibodies
Interferon-γ autoantibodies increase the risk of disseminated nontuberculous mycobacterial infections. Addition of rituximab to antibiotics accelerates and improves outcomes, but refractory infections can occur due to persistent production of autoantibodies. We combined bortezomib with rituximab to...
Main Authors: | Joseph M. Rocco, Lindsey B. Rosen, Gloria H. Hong, Jennifer Treat, Samantha Kreuzburg, Steven M. Holland, Christa S. Zerbe |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-01-01
|
Series: | Journal of Translational Autoimmunity |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589909021000228 |
Similar Items
-
Interferon-γ Autoantibodies as Predisposing Factor for Nontuberculous Mycobacterial Infection
by: Florent Valour, et al.
Published: (2016-06-01) -
Nontuberculous mycobacterial axillary lymphadenitis in children
by: Jerome A. Lindeboom, et al.
Published: (2021-05-01) -
Nontuberculous mycobacterial empyema in an immunocompetent child
by: Ira Shah, et al.
Published: (2018-01-01) -
Clinical and Therapeutic Features of Pulmonary Nontuberculous Mycobacterial Disease, Rio de Janeiro, Brazil
by: Karla Gripp Couto de Mello, et al.
Published: (2013-03-01) -
Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016
by: Hyewon Lee, et al.
Published: (2019-03-01)